CereMark touts new patents for PET Alzheimer's agent

By AuntMinnie.com staff writers

August 4, 2022 -- Radiopharmaceutical developer CereMark announced that additional patents have been awarded to the University of California, Los Angeles (UCLA) for a PET agent that the company licensed from the university for the imaging of Alzheimer's disease.

The patents are associated with F-18 flornaptitril (also known as F-18 FDDNP), a biomarker for the detection, development, and progression of Alzheimer's disease, as well as chronic traumatic encephalopathy and other neurodegenerative diseases.

The patents cover a synthesizing method that allows for high radiochemical yields and short manufacturing times for administration.

CereMark is UCLA's only licensee for the development and commercialization of F-18 flornaptitril, and the company is preparing for a phase 3 clinical multisite study required for U.S. Food and Drug Administration approval.

Copyright © 2022 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking